RRM1 and pancreatic neoplasm: For example, upon gemcitabine resistance acquisition in pancreatic cancer as well as in non-small-cell lung carcinoma, an amplification of one of the main targets of gemcitabine, ribonucleotide reductase catalytic subunit M1 (RRM1), was observed.